The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Until today this year the stock’s price performance recorded an increase of 12.63%. However, over the last six months, the performance has been stronger by -21.90%. The price of KRON increased 15.29% over the last 30 days. And in the last five days, it has surged by 9.18%.
Kronos Bio Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $1.60 on 07/16/24, while the lowest price for the same duration was marked at $0.69 on 05/24/24.
52-week price history of KRON Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Kronos Bio Inc’s current trading price is -33.12% away from its 52-week high, while its distance from the 52-week low is 55.07%. The stock’s price range during this period has varied between$0.69 and $1.60. The Kronos Bio Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.58 million for the day, a figure considerably higher than their average daily volume of 0.28 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Kronos Bio Inc (KRON) has experienced a quarterly rise of 11.46% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 64.56M and boasts a workforce of 63 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9570, with a change in price of +0.0747. Similarly, Kronos Bio Inc recorded 206,364 in trading volume during the last 100 days, posting a change of +7.51%.
KRON’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for KRON stands at 0.23. Similarly, the long-term debt-to-equity ratio is also 0.20.
KRON Stock Stochastic Average
Kronos Bio Inc’s raw stochastic average for the past 50 days is presently 93.10%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 89.99%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 80.02% and 77.08%, respectively.
